id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
EPA_FRDOC_0001-30344,EPA,EPA_FRDOC_0001,"Environmental Impact Statements; Availability, etc.",Notice,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T13:38:49Z,2023-28749,0,0,0900006486365be4
EPA-HQ-OPP-2023-0597-0001,EPA,EPA-HQ-OPP-2023-0597,Exemption: Clothianidin,Notice,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,2024-01-17T04:59:59Z,2024-01-17T02:01:01Z,2023-28772,0,0,0900006486365b43
EPA-R09-OAR-2023-0599-0002,EPA,EPA-R09-OAR-2023-0599,Maricopa County Rule 100 letter signed,Supporting & Related Material,,2023-12-29T05:00:00Z,2023,12,,,2023-12-30T01:55:16Z,,0,0,09000064863670ec
EPA-R09-OAR-2023-0599-0003,EPA,EPA-R09-OAR-2023-0599,TSD MCAQD NSR Rule 100 2023-0599 12-4-2023,Supporting & Related Material,,2023-12-29T05:00:00Z,2023,12,,,2023-12-30T01:55:29Z,,0,0,0900006486366f6a
EPA-HQ-OLEM-2020-0107-0983,EPA,EPA-HQ-OLEM-2020-0107,"Memo to docket Meeting with Duke Energy November 29, 2023 with attached presentation",Supporting & Related Material,Meeting Materials,2023-12-29T05:00:00Z,2023,12,,,2023-12-30T01:32:20Z,,0,0,09000064863670eb
EPA-HQ-OPP-2023-0597-0002,EPA,EPA-HQ-OPP-2023-0597,FIFRA Section 18 Emergency Exemption Renewal Request For Belay Insecticide (clothianidin; 23.0%) (24FL01- Application - 20231117),Supporting & Related Material,,2023-12-29T05:00:00Z,2023,12,,,2023-12-30T01:38:22Z,,0,0,090000648634947f
EPA-R06-OAR-2022-0907-0006,EPA,EPA-R06-OAR-2022-0907,"AR039.06 Air Quality State Implementation Plans; Approvals and Promulgations; Arkansas; Revisions to Rule 19: Rules of the Arkansas Plan of Implementation for Air Pollution Control, Final rule, 5 pages.",Rule,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T15:30:24Z,2023-28497,0,0,0900006486365b3b
EPA-R09-OAR-2023-0449-0001,EPA,EPA-R09-OAR-2023-0449,Air Quality State Implementation Plans; Approvals and Promulgations: California; San Luis Obispo County Air Pollution Control District; New Source Review,Proposed Rule,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,2024-01-30T04:59:59Z,2023-12-29T20:05:11Z,2023-28750,0,0,0900006486365bdf
EPA-R09-OAR-2023-0599-0004,EPA,EPA-R09-OAR-2023-0599,Rule100-SIP Revision,Supporting & Related Material,,2023-12-29T05:00:00Z,2023,12,,,2023-12-30T01:55:41Z,,0,0,0900006486366f6b
EPA-HQ-ORD-2012-0830-0100,EPA,EPA-HQ-ORD-2012-0830,Availability of the Benchmark Dose (BMD) Model Code and BMD Modeling Output Files for the Draft Integrated Risk Information System (IRIS) Toxicological Review of Inorganic Arsenic,Notice,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,2024-01-17T04:59:59Z,2024-01-18T02:00:45Z,2023-28766,0,0,0900006486365bde
FDA-2022-E-2011-0005,FDA,FDA-2022-E-2011,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:16Z,,0,0,0900006486365699
FDA-2022-E-2010-0005,FDA,FDA-2022-E-2010,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:02Z,,0,0,0900006486365697
FDA-2022-E-2014-0005,FDA,FDA-2022-E-2014,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:09:57Z,,0,0,0900006486365a1a
FDA-2022-N-2226-0144,FDA,FDA-2022-N-2226,Tab C - FDA Salt Substitutes - NPRM and PRIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:42:15Z,,0,0,0900006486366ef1
FDA-2019-N-4750-0041,FDA,FDA-2019-N-4750,Memorandum to FDA DMS on Partially Hydrogenated Oils,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:12Z,,0,0,0900006486365e65
FDA-2019-N-4750-0045,FDA,FDA-2019-N-4750,Tab A - PHOs RIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:30Z,,0,0,0900006486365e69
FDA-1997-S-0006-2049,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to Vedistry Pvt Ltd.,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:52Z,,0,0,090000648635f527
FDA-1997-S-0006-2046,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:18Z,,0,0,090000648635f0c5
FDA-1997-S-0006-2043,FDA,FDA-1997-S-0006,Courtesy letter and related material from CFSAN to Arbonne International LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:03:49Z,,0,0,090000648635de73
FDA-1997-S-0006-2048,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:42Z,,0,0,090000648635f525
FDA-2023-H-5636-0001,FDA,FDA-2023-H-5636,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:34:31Z,,0,0,0900006486361437
FDA-2022-E-2012-0005,FDA,FDA-2022-E-2012,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:29Z,,0,0,090000648636569b
FDA-2019-E-3218-0005,FDA,FDA-2019-E-3218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:03:25Z,,0,0,0900006486365a16
FDA-2022-E-2013-0005,FDA,FDA-2022-E-2013,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:42Z,,0,0,0900006486365ce2
FDA-2019-N-4750-0048,FDA,FDA-2019-N-4750,Tab B - PHOs PRIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:55Z,,0,0,0900006486365e8c
FDA-2019-N-4750-0051,FDA,FDA-2019-N-4750,Tab C - PHOs NPRM - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:23Z,,0,0,0900006486365e91
FDA-2023-H-5667-0001,FDA,FDA-2023-H-5667,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:57:02Z,,0,0,0900006486365657
FDA-1997-S-0006-2044,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to CalmCo LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:03:58Z,,0,0,090000648635d608
FDA-2023-H-5657-0001,FDA,FDA-2023-H-5657,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T19:24:51Z,,0,0,0900006486366f65
FDA-2023-H-5410-0001,FDA,FDA-2023-H-5410,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T18:58:41Z,,0,0,0900006486365c81
FDA-2019-N-4750-0046,FDA,FDA-2019-N-4750,Tab B - PHOs DFR - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:46Z,,0,0,0900006486365e6a
FDA-2019-N-4750-0047,FDA,FDA-2019-N-4750,Tab B - PHOs NPRM - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:50Z,,0,0,0900006486365e6b
FDA-2019-N-4750-0050,FDA,FDA-2019-N-4750,Tab C - PHOs DFR - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:18Z,,0,0,0900006486365e8e
FDA-2023-H-5663-0001,FDA,FDA-2023-H-5663,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:52:49Z,,0,0,090000648636564e
FDA-2023-H-5661-0001,FDA,FDA-2023-H-5661,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:39:48Z,,0,0,0900006486366919
FDA-2023-H-5662-0001,FDA,FDA-2023-H-5662,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:41:58Z,,0,0,090000648636692b
FDA-2022-N-2226-0142,FDA,FDA-2022-N-2226,Tab A - FDA Salt Substitutes NPRM and PRIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:41:54Z,,0,0,0900006486366edd
FDA-2022-N-2226-0141,FDA,FDA-2022-N-2226,Memorandum to FDA DMS on Salt Substitutes NPRM,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:41:49Z,,0,0,0900006486366eda
FDA-2023-U-5565-0001,FDA,FDA-2023-U-5565,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:07:31Z,,0,0,09000064863612e4
FDA-2023-H-5665-0001,FDA,FDA-2023-H-5665,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:15:06Z,,0,0,0900006486365654
FDA-2023-H-5269-0001,FDA,FDA-2023-H-5269,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:24:00Z,,0,0,0900006486365665
FDA-1997-S-0006-2050,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to CalmCo LLC,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:05:03Z,,0,0,090000648635f529
FDA-2019-E-5256-0005,FDA,FDA-2019-E-5256,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T13:26:57Z,,0,0,090000648636562d
FDA-2019-N-4750-0044,FDA,FDA-2019-N-4750,Tab A - PHOs PRIA - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:25Z,,0,0,0900006486365e68
FDA-2019-N-4750-0049,FDA,FDA-2019-N-4750,Tab B - PHOs RIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:01Z,,0,0,0900006486365e8d
FDA-2019-N-4750-0053,FDA,FDA-2019-N-4750,Tab C - PHOs RIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:32Z,,0,0,0900006486365e93
FDA-2023-H-5666-0001,FDA,FDA-2023-H-5666,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:46:57Z,,0,0,0900006486364c23
FDA-2023-H-5660-0001,FDA,FDA-2023-H-5660,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:38:09Z,,0,0,09000064863665e4
FDA-2023-H-5672-0001,FDA,FDA-2023-H-5672,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:28:45Z,,0,0,0900006486365662
FDA-2019-E-3017-0005,FDA,FDA-2019-E-3017,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:13:37Z,,0,0,09000064863656c8
FDA-2022-E-2016-0005,FDA,FDA-2022-E-2016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:10:40Z,,0,0,0900006486365692
FDA-2019-E-3287-0005,FDA,FDA-2019-E-3287,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:14:00Z,,0,0,0900006486365c60
FDA-2023-H-5673-0001,FDA,FDA-2023-H-5673,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T15:05:01Z,,0,0,090000648636568b
FDA-2023-H-5674-0001,FDA,FDA-2023-H-5674,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T15:08:02Z,,0,0,0900006486365c7b
FDA-2023-H-5603-0001,FDA,FDA-2023-H-5603,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:34:53Z,,0,0,0900006486365669
FDA-2019-N-4750-0052,FDA,FDA-2019-N-4750,Tab C - PHOs PRIA - Final to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:57:27Z,,0,0,0900006486365e92
FDA-2023-H-5177-0001,FDA,FDA-2023-H-5177,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T15:00:37Z,,0,0,09000064862c07f3
FDA-2023-H-5658-0001,FDA,FDA-2023-H-5658,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2024-01-02T05:00:00Z,,2024-01-02T13:25:31Z,,0,0,0900006486366f68
FDA-2022-N-2226-0143,FDA,FDA-2022-N-2226,Tab B - FDA Salt Substitutes NPRM and PRIA - Comparison OMB Original to Final,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T17:42:10Z,,0,0,0900006486366ee2
FDA-1997-S-0006-2045,FDA,FDA-1997-S-0006,Courtesy letter and related material from FDA CFSAN to Robinson Pharma,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:07Z,,0,0,090000648635f0c2
FDA-1997-S-0006-2047,FDA,FDA-1997-S-0006,"Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd.",Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T18:04:30Z,,0,0,090000648635f521
FDA-2023-H-5664-0001,FDA,FDA-2023-H-5664,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T17:02:17Z,,0,0,0900006486365651
FDA-2023-H-5670-0001,FDA,FDA-2023-H-5670,Complaint,Other,Complaint,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T16:51:21Z,,0,0,0900006486366931
FDA-2019-N-4750-0042,FDA,FDA-2019-N-4750,Tab A - PHOs DFR - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:16Z,,0,0,0900006486365e66
FDA-2022-E-2009-0005,FDA,FDA-2022-E-2009,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:11:49Z,,0,0,0900006486365c63
FDA-2019-N-4750-0043,FDA,FDA-2019-N-4750,Tab A - PHOs NPRM - Original to OMB,Supporting & Related Material,Background Material,2023-12-29T05:00:00Z,2023,12,,,2023-12-29T16:56:21Z,,0,0,0900006486365e67
FWS-R8-ES-2023-0191-0001,FWS,FWS-R8-ES-2023-0191,"Draft Habitat Conservation Plan and Draft Environmental Assessment; Sacramento Municipal Utility District Operations, Maintenance, and New Construction Habitat Conservation Plan, Sacramento County, CA",Notice,,2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,2024-01-30T04:59:59Z,2024-01-30T02:00:37Z,2023-28719,0,0,0900006486365625
EPA-R09-OAR-2023-0203-0009,EPA,EPA-R09-OAR-2023-0203,Air Quality State Implementation Plans; Approvals and Promulgations: California State Implementation Plan; San Francisco Bay Area,Rule,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:46:20Z,2023-28494,0,0,09000064863617e1
EPA-R09-OAR-2023-0203-0010,EPA,EPA-R09-OAR-2023-0203,Final Docket Index for the Approval and Promulgation of Implementation Plans; Revisions to the CA SIP; SF Bay Area,Supporting & Related Material,,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T02:07:36Z,,0,0,0900006486361443
EPA-HQ-OPPT-2015-0436-0044,EPA,EPA-HQ-OPPT-2015-0436,FAQs,Supporting & Related Material,,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:38:35Z,,0,0,0900006484f7a78f
EPA-R09-OAR-2023-0203-0011,EPA,EPA-R09-OAR-2023-0203,E. 88 FR 89587 Approval And Promulgation of Implementation Plans; Revisions to the CA State Plan; SF Bay Area,Supporting & Related Material,,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T02:07:48Z,,0,0,0900006486361445
EPA-R10-OAR-2019-0647-0007,EPA,EPA-R10-OAR-2019-0647,"Air Quality State Implementation Plans; Approvals and Promulgations: Washington; Excess Emissions, Startup, Shutdown, and Malfunction Revisions",Rule,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T16:35:51Z,2023-28294,0,0,09000064863618c5
EPA-R02-OAR-2023-0175-0006,EPA,EPA-R02-OAR-2023-0175,Air Quality State Implementation Plans; Approvals and Promulgations: New York; Emission Statement Program,Rule,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-29T19:16:51Z,2023-28343,0,0,0900006486361798
EPA-HQ-OA-2013-0320-0031,EPA,EPA-HQ-OA-2013-0320,Guidance: Assessing Environmental Justice in Regulatory Analysis,Notice,Extension of Comment Period,2023-12-28T05:00:00Z,2023,12,,,2023-12-28T15:37:42Z,2023-28598,0,0,0900006486361790
EPA-HQ-OW-2015-0680-0423,EPA,EPA-HQ-OW-2015-0680,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Use of Lead Free Pipes, Fittings, Fixtures, Solder and Flux for Drinking Water (Renewal)",Notice,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-01-30T04:59:59Z,2023-12-28T15:01:47Z,2023-28640,0,0,0900006486361660
EPA-HQ-OPPT-2015-0436-0043,EPA,EPA-HQ-OPPT-2015-0436,Supporting Statement for OMB Review,Supporting & Related Material,ICR Supporting Statement,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:38:47Z,,0,0,0900006484f7a78e
EPA-HQ-OPPT-2023-0309-0021,EPA,EPA-HQ-OPPT-2023-0309,"The Asbestos Medicine Seminar November 15-17, 2023, Retrospective: The DRI Presentation of 2023, The North Carolina Asbestos Plants, Revisited: 2023",Supporting & Related Material,Publication - Copyrighted Materials,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:39:26Z,,0,0,0900006486361325
EPA-HQ-OLEM-2023-0244-0002,EPA,EPA-HQ-OLEM-2023-0244,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Disposal of Coal Combustion Residuals From Electric Utilities (Renewal)",Notice,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-01-30T04:59:59Z,2023-12-28T15:15:36Z,2023-28639,0,0,090000648636172c
EPA-R06-OAR-2023-0090-0014,EPA,EPA-R06-OAR-2023-0090,"OK043.13 Air Quality State Implementation Plans; Approvals and Promulgations: Oklahoma; Revisions to Air Pollution Control Rules, Final rule, first 4 pages",Rule,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:28:21Z,2023-28496,0,0,09000064863618c7
EPA-HQ-OPPT-2015-0436-0047,EPA,EPA-HQ-OPPT-2015-0436,CDX User Guide,Supporting & Related Material,Publication - USEPA,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:39:00Z,,0,0,0900006484f7a792
EPA-HQ-OPPT-2023-0309-0020,EPA,EPA-HQ-OPPT-2023-0309,Letter Peer Reviewer Comments on the White Paper: Quantitative Human Health Approach to be Applied in the Risk Evaluation for Asbestos Part 2—Supplemental Evaluation including Legacy Uses and Associated Disposals of Asbestos,Supporting & Related Material,Memorandum,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:39:13Z,,0,0,0900006486361307
EPA-HQ-OPPT-2015-0436-0045,EPA,EPA-HQ-OPPT-2015-0436,Consultation - TSCA Section 4 Test Orders Website Update,Supporting & Related Material,,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:38:22Z,,0,0,0900006484f7a790
EPA-HQ-OW-2017-0300-1915,EPA,EPA-HQ-OW-2017-0300,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Lead and Copper Rule Revisions",Notice,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-01-30T04:59:59Z,2023-12-28T15:24:27Z,2023-28641,0,0,0900006486361915
EPA-HQ-OPPT-2015-0436-0042,EPA,EPA-HQ-OPPT-2015-0436,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Generic Clearance for TSCA Section 4 Test Rules, Test Orders, Enforceable Consent Agreements, Voluntary Data Submissions, and Exemptions From Testing Requirements (Renewal)",Notice,,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-01-30T04:59:59Z,2023-12-28T15:09:11Z,2023-28663,0,0,09000064863616e9
EPA-HQ-OPPT-2015-0436-0046,EPA,EPA-HQ-OPPT-2015-0436,Emergency Request Memorandum to OMB,Supporting & Related Material,Memorandum,2023-12-28T05:00:00Z,2023,12,,,2023-12-29T01:38:09Z,,0,0,0900006484f7a791
FDA-2023-H-5639-0001,FDA,FDA-2023-H-5639,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:19:51Z,,0,0,090000648635d710
FDA-2023-H-5650-0001,FDA,FDA-2023-H-5650,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:50:58Z,,0,0,0900006486361319
FDA-2023-D-5408-0002,FDA,FDA-2023-D-5408,Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Guidance for Industry - Final Guidance,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2024-11-12T06:24:20Z,,1,0,090000648635c332
FDA-2021-N-0039-0002,FDA,FDA-2021-N-0039,"Electronic Submissions; Update to the Specifications for Preparing and
Submitting Postmarket Individual Case Safety Reports for Vaccines; Technical
Specification",Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2024-11-12T06:21:06Z,2023-28594,1,0,090000648636182b
FDA-2023-H-5647-0001,FDA,FDA-2023-H-5647,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:23:02Z,,0,0,0900006486361407
FDA-2023-H-5648-0001,FDA,FDA-2023-H-5648,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:26:47Z,,0,0,090000648636140a
FDA-2023-H-5643-0001,FDA,FDA-2023-H-5643,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T17:54:09Z,,0,0,09000064863612e1
FDA-2023-H-5645-0001,FDA,FDA-2023-H-5645,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T21:03:53Z,,0,0,0900006486364790
FDA-2023-D-4177-0021,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Revised Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T15:10:09Z,2023-28595,0,0,090000648636165b
FDA-2023-D-4299-0002,FDA,FDA-2023-D-4299,Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-03-28T03:59:59Z,2024-11-12T06:25:10Z,,1,0,0900006486364261
FDA-2023-H-5637-0001,FDA,FDA-2023-H-5637,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2024-01-01T05:00:00Z,,2024-01-01T19:25:25Z,,0,0,09000064863647c6
FDA-2020-Q-1295-0026,FDA,FDA-2020-Q-1295,Withdrawal request for docket number FDA-2020-Q-1295,Other,Withdrawal,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:40:58Z,,0,0,0900006486364403
FDA-2020-Q-1295-0027,FDA,FDA-2020-Q-1295,FDA response to a withdrawal request for CA and Migraine Final,Other,Acknowledgement Letter/Receipt,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:41:04Z,,0,0,0900006486364405
FDA-2023-D-4177-0022,FDA,FDA-2023-D-4177,Quality Considerations for Topical Ophthalmic Drug Products; Guidance for Industry; Draft Guidance,Other,Guidance,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,2024-02-27T04:59:59Z,2025-02-04T02:01:06Z,,1,0,09000064863613f7
FDA-2023-H-5644-0001,FDA,FDA-2023-H-5644,Complaint,Other,Complaint,2023-12-28T05:00:00Z,2023,12,2023-12-28T05:00:00Z,,2023-12-28T18:27:41Z,,0,0,09000064863612e7